Lea Eslava-Kim, PharmD

Drug Information Specialist https://www.endocrinologyadvisor.com

Lea Eslava-Kim, PharmD, is a Drug Information Specialist for MPR. She received her doctorate in pharmacy from the Ernest Mario School of Pharmacy, Rutgers University and completed her pharmacy residency at Clara Maass Medical Center. She is a licensed pharmacist.

All articles by Lea Eslava-Kim, PharmD

Diabetes

Injection-Free GLP-1 Receptor Agonist for T2D Under FDA Review

The Food and Drug Administration has accepted a New Drug Application for ITCA 650 (Intarcia Therapeutics) for further review in patients with type 2 diabetes.

Lea Eslava-Kim, PharmD

February 8, 2017

Diabetes

FDA to Review Insulin Glargine/Lixisenatide Combination for Type 2 Diabetes

Sanofi has submitted an NDA to the FDA for its investigational fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide as a single daily injection for the treatment of adults with type 2 diabetes.

Lea Eslava-Kim, PharmD

December 28, 2015

Diabetes

Omarigliptin Achieves Primary Efficacy Endpoint in Phase 3 Study

Once-weekly DPP-4 inhibitor achieved its primary efficacy endpoint in a phase 3 study comparing it with once daily Januvia.

Lea Eslava-Kim, PharmD

September 16, 2015